ATC codes: P02CF01
Scabies ICD11 code: 1G74
Medicine type
Chemical agent
List type
Oral > Solid: 3 mg tablet (scored)
EML status history
First added in 2019 (TRS 1021)
Also recommended for children
Therapeutic equivalence
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Expert Committee recommendation
The Expert Committee recommended listing of ivermectin on the core list of the EML and EMLc for the new indication of treatment of scabies. The Committee noted that oral ivermectin treatment is associated with comparable effectiveness to topical therapies and has acceptable safety. The Committee also noted the effectiveness of ivermectin as a public health intervention when delivered via mass drug administration programmes. The Committee considered that the ease of oral administration compared to topical administration may also represent an advantage for patients in terms of compliance.
The application requested listing of ivermectin on the core list of the EML and EMLc for the new indication of treatment of scabies. Ivermectin is currently included on the EML and EMLc as an intestinal anthelminthic and antifilarial treatment. Only topical therapies for scabies (benzyl benzoate and permethrin) are currently included on the Model Lists.
Public health relevance
Scabies is seen in all countries. In many resource-poor settings, prevalence rates of infestation can exceed 20% of the population and the most vulnerable members of society, children (1) and the elderly, are at highest risk. In 2015, the global prevalence of scabies was over 200 million (2). Globally, scabies was responsible for 0.21% of disability-adjusted life-years (DALYs) from all conditions studied by the Global Burden of Disease Study 2015 (2). A major complication of scabies with lasting consequences for health, seen most in resource-poor settings, is symptomatic acute glomerulonephritis (AGN), which was reported in 10% of children in a survey in northern Australia, while 24% had microscopic haematuria (3). AGN was closely linked to skin sores due to streptococcal infection, and scabies was identified as the principal cause. Scabies infestation is also an epidemiological risk factor for rheumatic fever and there is a strong association with scabies-associated streptococcal infections (4). One study has identified a possible link between scabies and bacterial sepsis caused by Staphylococcus aureus in infants in the Gambia (5). Household economic loss due to scabies is also a major problem in resource-poor communities. A study in rural Mexico indicated that families were spending a significant part of their household income on ineffective topical treatment of scabies (US$ 24) over each 3-month period, impacting the ability to purchase other commodities, including food (6). Scabies in resource-poor environments is therefore both a potential cause of serious morbidity and a source of financial burden. Its high prevalence places a huge burden on stretched health care resources.
The application presented the results of a 2018 Cochrane systematic review of 15 studies (1896 participants) comparing topical permethrin, systemic ivermectin or topical ivermectin for treatment of scabies (7). The response to oral ivermectin was found to be equivalent to the response to topical permethrin, two and four weeks after treatment. 200 μg/kg oral ivermectin (was associated with slightly lower rates of complete clearance after one week compared to permethrin 5% cream. Using the average clearance rate of 65% in the trials with permethrin, the illustrative clearance with ivermectin was 43% (RR 0.65, 95%CI 0.54 to 0.78; 613 participants, six studies; low certainty evidence). After two weeks, there was no significant difference (illustrative clearance of permethrin 74% compared to ivermectin 68%; RR 0.91, 95%CI 0.76 to 1.08; 459 participants, five studies; low certainty evidence). In this review, there did not appear to be any advantage in repeated treatments in conventional cases of scabies. Hence treatment with one to three doses of ivermectin or one to three applications of permethrin led to little or no difference in rates of complete clearance after four weeks follow‐up (illustrative cures with one to three applications of permethrin 93% and with one to three doses of ivermectin 86%; RR 0.92, 95%CI 0.82 to 1.03; 581 participants, five studies; low certainty evidence). Seven days after treatment with oral ivermectin 200 μg/kg or one application of permethrin 5% lotion, there was little or no difference in complete clearance rates (illustrative cure rates: permethrin 73%, ivermectin 68%; RR 0.93, 95%CI 0.74 to 1.17; 120 participants, one study; moderate certainty evidence). After two weeks, one initial dose of systemic ivermectin compared to one application of permethrin lotion produced similar complete clearance rates (extrapolated cure rates: 67% in both groups; RR 1.00, 95%CI 0.78 to 1.29; 120 participants, one study; low certainty evidence). The application also presented the findings of numerous individual studies of ivermectin versus various topical agents for scabies that supported the comparative effectiveness of oral ivermectin (8–18). The application presented evidence of the effectiveness of ivermectin for treating scabies when delivered through mass drug administration programmes. Studies in Solomon Islands (19, 20), Australia (21), Brazil (22) and Fiji (23) all showed mass drug administration of ivermectin to be an effective public health intervention. There is some evidence from case reports and case series that oral ivermectin (with or without topical scabicides) is effective in the treatment of crusted scabies (24–28). Crusted scabies is a hyper-transmissible form of scabies where patients are infected with very large populations of scabies mites. It is mainly seen in those who are immunocompromised including HIV-infected individuals, transplant recipients and those on high doses immuno-modulating drugs or biologic agents; it may also occur in endemic settings in apparently healthy individuals. It is rare but can cause a major problem with transmission to susceptible populations.
Evidence for the safety of ivermectin has been evaluated when it was considered for listing on the EML for other indications. In terms of safety of oral ivermectin for treatment of scabies, the Cochrane systematic review reported moderate certainty evidence of no withdrawals due to adverse events in either the oral ivermectin or topical permethrin treatment groups. There was moderate certainty evidence of little or no difference between treatment groups for the proportion of participants who experienced at least one adverse event two weeks after initiation of treatment. After four weeks, ivermectin was associated with a larger proportion of participants with at least one adverse event (RR 1.30, 95%CI 0.35 to 4.83; 502 participants, four studies; low certainty evidence). Most side-effects reported in other studies were transient and mild. Loose stool, fatigue and headache were most frequently reported, and the incidence among the randomized control trials of all side-effects was highest in the studies involving children. When ivermectin is administered to subjects with high Loa loa microfilariaemia, severe adverse reactions such as neurological signs, encephalopathy and coma have been reported (29). In Loa loa endemic countries, potential coinfection with this parasite has to be considered prior to using ivermectin. There were a total of 1656 reports for ivermectin in VigiBase (out of a total of over 14 million reports in the database). Reports in males and females were of similar proportions. The majority of reports were in adults aged 18 years and older. The most commonly reported adverse drug reactions (ADRs) for ivermectin alone and ivermectin co-administered with albendazole included pruritus, headache, dizziness, vomiting, rash, urticarial and diarrhoea. Most reported ADRs were considered to be minor and transient. Safety of ivermectin in pregnant women or children under 15 kg body weight has not been established.
Cost / cost effectiveness
The application stated that no cost-benefit analyses on the use of ivermectin in scabies have been undertaken, but proposes that effective interventions with ivermectin may reduce personal, institutional and governmental expenditure.
WHO guidelines
WHO guidelines on the treatment of skin and oral HIV-associated conditions in children and adults (30) recommend treatment with oral ivermectin (200 μg/ kg) for mild/moderate scabies in HIV-infected children and adults if topical permethrin treatment is not feasible or there is a poor response (Strong recommendation, low quality evidence). The guidelines also recommend two doses of oral ivermectin for treatment of HIV-infected children ≥15 kg and adults with severe or crusted scabies.
Ivermectin has wide market availability. Generic brands are available.
1. Kearns T, Clucas D, Connors C, Currie BJ, Carapetis JR, Andrews RM. Clinic attendances during the first 12 months of life for Aboriginal children in five remote communities of northern Australia. PLoS One. 2013;8(3):e58231. 2. Karimkhani C, Colombara DV, Drucker AM, Norton SA, Hay R, Engelman D et al. The global burden of scabies: a cross-sectional analysis from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(12):1247–54. 3. Streeton CL, Hanna JN, Messer RD, Merianos A. An epidemic of acute post-streptococcal glomerulonephritis among aboriginal children. J Paediatr Child Health. 1995;31(3):245–8. 4. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis. 2004;4(4):240–5. 5. Mulholland EK, Ogunlesi OO, Adegbola RA, Weber M, Sam BE, Palmer A et al. Etiology of serious infections in young Gambian infants. Pediatr Infect Dis J. 1999;18(10 Suppl):S35–41. 6. Hay RJ, Estrada Castanon R, Alarcon Hernandez H, Chavez Lopez G, Lopez Fuentes LF, Paredes Solis S et al. Wastage of family income on skin disease in Mexico. BMJ. 1994;309(6958):848. 7. Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev. 2018;4:CD012994. 8. Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012;78(5):605–10. 9. Mushtaq A, Khurshid K, Pal SS. Comparison of efficacy and safety of oral ivermectin with topical permethrin in treatment of scabies. JPAD. 2010;20:227–31. 10. Rohatgi V, S. Reddy N, Vagge D. A prospective, randomized, open labelled, comparative study of efficacy and cost effectiveness of permethrin and ivermectin in 5-15 years age group patients with scabies in a tertiary care hospital. Indian J Pharmacol. 2013;45:S45. 11. Manjhi PK, Sinha RI, Kumar M, Sinha KI. Comparative study of efficacy of oral ivermectin versus some topical antiscabies drugs in the treatment of scabies. J Clin Diagn Res. 2014;8(9):Hc01–4. 12. Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol. 2009;41(1):9–14. 13. Ly F, Caumes E, Ndaw CA, Ndiaye B, Mahe A. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull World Health Organ. 2009;87(6):424–30. 14. Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health. 2002;38(4):401–4. 15. Goldust M, Rezaee E, Raghifar R, Naghavi-Behzad M. Ivermectin vs. lindane in the treatment of scabies. Ann Parasitol. 2013;59(1):37–41. 16. Goldust M, Rezaee E, Raghifar R. Comparison of oral ivermectin versus crotamiton 10% cream in the treatment of scabies. Cutan Ocul Toxicol. 2014;33(4):333–6. 17. Madan V, Jaskiran K, Gupta U, Gupta DK. Oral ivermectin in scabies patients: a comparison with 1% topical lindane lotion. J Dermatol. 2001;28(9):481–4. 18. Sule HM, Thacher TD. Comparison of ivermectin and benzyl benzoate lotion for scabies in Nigerian patients. Am J Trop Med Hyg. 2007;76(2):392–5. 19. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, Wate C et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull World Health Organ. 2005;83(1):34–42. 20. Marks M, Taotao-Wini B, Satorara L, Engelman D, Nasi T, Mabey DC et al. Long Term Control of Scabies Fifteen Years after an Intensive Treatment Programme. PLoS Negl Trop Dis. 2015; 9(12):e0004246. 21. Kearns TM, Speare R, Cheng AC, McCarthy J, Carapetis JR, Holt DC et al. Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community. PLoS Negl Trop Dis. 2015;9(10):e0004151. 22. Worth C, Heukelbach J, Fengler G, Walter B, Liesenfeld O, Hengge U et al. Acute morbidity associated with scabies and other ectoparasitoses rapidly improves after treatment with ivermectin. Pediatr Dermatol. 2012;29(4):430–6. 23. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L et al. Mass Drug Administration for Scabies Control in a Population with Endemic Disease. N Engl J Med. 2015; 373(24):2305–13. 24. Nofal A. Variable response of crusted scabies to oral ivermectin: report on eight Egyptian patients. J Eur Acad Dermatol Venereol. 2009;23(7):793–7. 25. Ortega-Loayza AG, McCall CO, Nunley JR. Crusted scabies and multiple dosages of ivermectin. J Drugs Dermatol. 2013;12(5):584–5. 26. Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect. 2005;50(5):375–81. 27. Sandre M, Ralevski F, Rau N. An elderly long-term care resident with crusted scabies. Can J Infect Dis Med Microbiol. 2015;26(1):39–40. 28. Yee BE, Carlos CA, Hata T. Crusted scabies of the scalp in a patient with systemic lupus erythematosus. Dermatol Online J. 2014;20(10). 29. WHO African Programme for Onchocerciasis Control (WHO/APOC). Programme for the Elimination of Neglected Diseases in Africa (PENDA): Strategic Plan of Action and Indicative Budget 2016– 2025 Ouagadougou: APOC; 2013. Available from http://www.who.int/apoc/en_apoc_strategic_ plan_2013_ok.pdf, accessed 29 September 2019. 30. Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults. Geneva: World Health Organization; 2014. Available from https://apps.who.int/iris/bitstream/ handle/10665/136863/9789241548915_eng.pdf, accessed 30 October 2019.